| Stage | XOM | % of rev | CVI | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $113B | 100.00% | $3.3B | 100.00% | XOM ×34.49 |
| Gross profit | $36.2B | 32.01% | $783M | 23.86% | XOM +8.1pp |
| Operating income | $21.4B | 18.93% | $724M | 22.07% | CVI +3.1pp |
| Pre-tax income | $21.2B | 18.77% | $704M | 21.46% | CVI +2.7pp |
| Net income | $16.0B | 14.16% | $563M | 17.16% | CVI +3.0pp |
| Stage | XOM | CVI | Gap · A − B |
|---|---|---|---|
| Revenue | $113B100.00% | $3.3B100.00% | XOM ×34.49 |
| Gross profit | 32.01%$36.2B | 23.86%$783M | XOM +8.1pp |
| Operating income | 18.93%$21.4B | 22.07%$724M | CVI +3.1pp |
| Pre-tax income | 18.77%$21.2B | 21.46%$704M | CVI +2.7pp |
| Net income |
| 14.16%$16.0B |
| 17.16%$563M |
| CVI +3.0pp |
No shared counterparties.